Balyasny Asset Management LLC Ac Immune Sa Transaction History

Balyasny Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.4 - $3.64 $62,018 - $94,061	25,841 New	25,841 $82,000
Q4 2021 Feb 14, 2022	SELL	$4.83 - $7.56 $3.54 Million - $5.54 Million	-733,180 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.2 - $8.34 $2.93 Million - $3.94 Million	472,324 Added 181.07%	733,180 $4.92 Million
Q2 2021 Aug 16, 2021	BUY	$6.04 - $8.37 $1.42 Million - $1.97 Million	234,798 Added 901.06%	260,856 $2.07 Million
Q1 2021 May 17, 2021	BUY	$5.32 - $8.96 $138,628 - $233,479	26,058 New	26,058 $198,000
Q1 2020 May 15, 2020	SELL	$4.24 - $9.89 $142,688 - $332,828	-33,653 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$4.56 - $8.78 $153,457 - $295,473	33,653 New	33,653 $287,000
Q1 2019 May 15, 2019	SELL	$3.65 - $11.68 $401,500 - $1.28 Million	-110,000 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$7.35 - $11.7 $3.21 Million - $5.11 Million	-437,054 Reduced 79.89%	110,000 $1.04 Million
Q3 2018 Nov 14, 2018	BUY	$7.88 - $16.45 $4.11 Million - $8.57 Million	520,953 Added 1995.91%	547,054 $4.38 Million
Q2 2018 Aug 14, 2018	BUY	$8.17 - $10.9 $213,245 - $284,500	26,101 New	26,101 $243,000

28.2M

150K

12.4K

Ticker ACIU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,413,504
Market Cap $296M
Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectiv...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.